Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Metabolic Screening in Patients With Donnai-Barrow Syndrome
Metabolic Screening in Patients With Donnai-Barrow Syndrome
Status: Enrolling
Updated:  11/7/2013
Massachusetts General Hospital
mi
from
Boston, MA
Metabolic Screening in Patients With Donnai-Barrow Syndrome
Metabolic Screening in Patients With Donnai-Barrow Syndrome
Status: Enrolling
Updated: 11/7/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Los Angeles, CA
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Aurora, CO
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Athens, GA
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Athens, GA
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Idaho Falls, ID
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Indianapolis, IN
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Missoula, MT
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Missoula, MT
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Omaha, NE
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Bridgewater, NJ
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Bridgewater, NJ
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Brooklyn, NY
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Chapel Hill, NC
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Chattanooga, TN
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Fort Worth, TX
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Seattle, WA
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Rituximab for Pulmonary Sarcoidosis
Rituximab as a Novel Therapy in Refractory Sarcoidosis: A Prospective Open-
Status: Enrolling
Updated:  12/9/2013
University of Cincinnati
mi
from
Cincinnati, OH
Rituximab for Pulmonary Sarcoidosis
Rituximab as a Novel Therapy in Refractory Sarcoidosis: A Prospective Open-
Status: Enrolling
Updated: 12/9/2013
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes
Inhibition of Absorption of Cytoxic Lipid Peroxidation Products and Abnormalities of Postprandial Endothelial Function by Spice Polyphenols Fed Together With High Fat Meat Patty in Men With Type 2 Diabetes Mellitus or Impaired Glucose Tolerance
Status: Enrolling
Updated:  12/10/2013
David Geffen School of Medicine, UCLA Center for Human Nutrtiion
mi
from
Los Angeles, CA
Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes
Inhibition of Absorption of Cytoxic Lipid Peroxidation Products and Abnormalities of Postprandial Endothelial Function by Spice Polyphenols Fed Together With High Fat Meat Patty in Men With Type 2 Diabetes Mellitus or Impaired Glucose Tolerance
Status: Enrolling
Updated: 12/10/2013
David Geffen School of Medicine, UCLA Center for Human Nutrtiion
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Tucson, AZ
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Tustin, CA
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Tustin, CA
Click here to add this to my saved trials
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Denver, CO
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
St. Louis, MO
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Greenville, TX
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Greenville, TX
Click here to add this to my saved trials
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Madison, WI
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Phoenix, AZ
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Tucson, AZ
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Washington,
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Evanston, IL
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
St. Louis, MO
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Las Vegas, NV
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Great Neck, NY
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Great Neck, NY
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Ridgewood, NY
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Ridgewood, NY
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Charlotte, NC
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Cincinnati, OH
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Nashville, TN
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Fort Worth, TX
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Grand Prairie, TX
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Grand Prairie, TX
Click here to add this to my saved trials
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
San Antonio, TX
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Comparison of Two Programs for Weight Loss and Impact on Metabolic Syndrome
Comparison of Two Programs for Weight Loss and Impact on Metabolic Syndrome
Status: Enrolling
Updated:  1/2/2014
University of Kentucky
mi
from
Lexington, KY
Comparison of Two Programs for Weight Loss and Impact on Metabolic Syndrome
Comparison of Two Programs for Weight Loss and Impact on Metabolic Syndrome
Status: Enrolling
Updated: 1/2/2014
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Effectiveness of Manual Physical Therapy to Improve Endocrine Levels in Women
Effectiveness of Manual Physical Therapy to Improve Endocrine Levels in Women
Status: Enrolling
Updated:  1/2/2014
Clear Passage Physical Therapy
mi
from
Gainesville, FL
Effectiveness of Manual Physical Therapy to Improve Endocrine Levels in Women
Effectiveness of Manual Physical Therapy to Improve Endocrine Levels in Women
Status: Enrolling
Updated: 1/2/2014
Clear Passage Physical Therapy
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Web-based Approach to Treating Cardiovascular Disease Risk in Employees With Metabolic Syndrome
Baptist Employee Healthy Heart Study (BEHHS) - A Novel Web-based Approach to Reduce Cardiovascular Disease Risk in a Diverse Employee Population With Metabolic Syndrome Via Diet and Lifestyle Change
Status: Enrolling
Updated:  1/10/2014
South Miami Heart Center Outpatient Services
mi
from
Miami, FL
A Web-based Approach to Treating Cardiovascular Disease Risk in Employees With Metabolic Syndrome
Baptist Employee Healthy Heart Study (BEHHS) - A Novel Web-based Approach to Reduce Cardiovascular Disease Risk in a Diverse Employee Population With Metabolic Syndrome Via Diet and Lifestyle Change
Status: Enrolling
Updated: 1/10/2014
South Miami Heart Center Outpatient Services
mi
from
Miami, FL
Click here to add this to my saved trials
Testosterone Replacement for Male Opioid Agonist Maintained Patients
Testosterone Replacement for Male Opioid Agonist Maintained Patients
Status: Enrolling
Updated:  1/13/2014
MRU, APT Foundation, Inc
mi
from
New Haven, CT
Testosterone Replacement for Male Opioid Agonist Maintained Patients
Testosterone Replacement for Male Opioid Agonist Maintained Patients
Status: Enrolling
Updated: 1/13/2014
MRU, APT Foundation, Inc
mi
from
New Haven, CT
Click here to add this to my saved trials
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Birmingham, AL
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Mobile, AL
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Evanston, IL
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Lexington, KY
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Garden City, NY
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Garden City, NY
Click here to add this to my saved trials
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
New York, NY
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Rochester, NY
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Nashville, TN
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Riverton, UT
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Riverton, UT
Click here to add this to my saved trials
Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
Status: Enrolling
Updated:  1/23/2014
Clinical Research Facility
mi
from
Miami, FL
Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
Status: Enrolling
Updated: 1/23/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials